Niraparib

Generic Name
Niraparib
Brand Names
Zejula
Drug Type
Small Molecule
Chemical Formula
C19H20N4O
CAS Number
1038915-60-4
Unique Ingredient Identifier
HMC2H89N35
Background

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...

Indication

Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

First Posted Date
2017-10-12
Last Posted Date
2024-05-29
Lead Sponsor
Tesaro, Inc.
Target Recruit Count
58
Registration Number
NCT03307785
Locations
🇺🇸

GSK Investigational Site, San Marcos, Texas, United States

PEN-866 in Patients With Advanced Solid Malignancies

First Posted Date
2017-07-18
Last Posted Date
2022-02-17
Lead Sponsor
Tarveda Therapeutics
Target Recruit Count
340
Registration Number
NCT03221400
Locations
🇺🇸

Florida Cancer Specialists - North, Saint Petersburg, Florida, United States

🇺🇸

Florida Cancer Specialists - South, Fort Myers, Florida, United States

🇺🇸

Florida Cancer Specialists - East, West Palm Beach, Florida, United States

and more 13 locations

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

First Posted Date
2017-07-06
Last Posted Date
2024-02-05
Lead Sponsor
Georgetown University
Target Recruit Count
23
Registration Number
NCT03209401
Locations
🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

🇺🇸

Sibley Memorial Hospital, Washington, District of Columbia, United States

🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 2 locations

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

First Posted Date
2017-07-02
Last Posted Date
2023-09-15
Lead Sponsor
University of Florida
Target Recruit Count
37
Registration Number
NCT03207347
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Orlando Health UF Health Cancer Center, Orlando, Florida, United States

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1
Completed
Conditions
Breast Cancer
Ovarian Cancer
Interventions
Drug: niraparib
Drug: everolimus
First Posted Date
2017-05-16
Last Posted Date
2024-08-01
Lead Sponsor
Avera McKennan Hospital & University Health Center
Target Recruit Count
14
Registration Number
NCT03154281
Locations
🇺🇸

Avera Cancer Institute, Sioux Falls, South Dakota, United States

Biomarker-based Study in R/M SCCHN

First Posted Date
2017-03-23
Last Posted Date
2023-11-03
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
340
Registration Number
NCT03088059
Locations
🇧🇪

CHU Saint-Pierre-Site Porte de Hal, Brussels, Belgium

🇮🇹

IRCCS - Fondazione G. Pascale, Napoli, Italy

🇬🇧

Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom

and more 30 locations

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

First Posted Date
2017-03-10
Last Posted Date
2023-10-10
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
14
Registration Number
NCT03076203
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

🇺🇸

Tulane University, New Orleans, Louisiana, United States

and more 3 locations

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

First Posted Date
2017-01-20
Last Posted Date
2017-04-17
Lead Sponsor
Tesaro, Inc.
Registration Number
NCT03025867

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Phase 2
Active, not recruiting
Conditions
Endometrial Cancer
Interventions
Drug: Niraparib
Drug: TSR-042
First Posted Date
2017-01-10
Last Posted Date
2024-01-30
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
51
Registration Number
NCT03016338
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

🇨🇦

London Regional Cancer Centre, London, Ontario, Canada

🇨🇦

Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 4 locations

The Drug Rediscovery Protocol (DRUP Trial)

First Posted Date
2016-10-05
Last Posted Date
2024-01-24
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
1550
Registration Number
NCT02925234
Locations
🇳🇱

Meander medisch centrum, Amersfoort, Netherlands

🇳🇱

Netherlands Cancer Institute, Amsterdam, Netherlands

🇳🇱

Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

and more 33 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy